Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Avectas

Main focus: Next-generation delivery technology for gene editing

Company stage: Pre-clinical

Diseases: Cancer

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Dublin, Ireland

Website: https://avectas.com/

Partners: ONK Therapeutics

Avectas develops its proprietary SOLUPORE® technology to genetically engineer T cells and natural killer (NK) cells to enable the next generation of gene-modified cell therapies. The company has established a collaboration with ONK Therapeutics, however, it yet has to disclose any proprietary or partnered therapeutic programmes.

Your Latest CMN News

CMN Weekly (26 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

Company: Avectas

Search CRISPR Medicine